🇺🇸 FDA
Pipeline program

OMP-59R5

59R5-002

Phase 2 small_molecule completed

Quick answer

OMP-59R5 for Stage IV Pancreatic Cancer is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Mereo BioPharma Group plc
Indication
Stage IV Pancreatic Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials